Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

BioSystem Development announces the release of AssayMAP MAb Titer Assay

BioSystem Development, LLC., a privately held life science analytics company, announces the release of the AssayMAP MAb Titer Assay for measuring antibody product concentrations (or titers) in bioprocess samples.

9 Dec 2009

Additional data from ALS patients enrolled in confirmatory Phase III STAR trial announced

AVANIR Pharmaceuticals, Inc. today announced additional data from the subset of patients with amyotrophic lateral sclerosis (ALS) enrolled in the confirmatory Phase III STAR trial.

9 Dec 2009

Roche to present data on its Herceptin, Avastin and T-DM1 studies at CTRC-AACR Symposium

Roche announced today that new 5 year follow-up data from two pivotal studies with Herceptin(R) (trastuzumab) in early breast cancer; key results from a study of Avastin(R) (bevacizumab) in the second-line treatment of advanced breast cancer and strong data on the use of trastuzumab-DM1 (T-DM1), the first antibody-drug conjugate in development for very advanced HER2-positive breast cancer, will all be presented during the CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) from 9 to 13 December 2009.

9 Dec 2009

Alternative, fast and safe process for producing large quantities of effective flu vaccines

A shortage of flu vaccines may soon become a problem of the past. Researcher Manon Cox has developed an alternative process for producing large quantities of safe and effective vaccines at twice to four times the usual speed. The process is based on using cells in bioreactors instead of fertilised chicken's eggs, which have a limited availability.

9 Dec 2009

Phase 3 clinical trial results of RG1068 to be discussed

Repligen Corporation announced today that the Company President and Chief Executive Officer, Walter C. Herlihy, Ph.D., will host a conference call and webcast on Wednesday, December 9th, 2009 at 8:30 a.m. EST, to discuss results of its Phase 3 clinical trial of RG1068 in MRI imaging of the pancreas.

9 Dec 2009

New IME-developed cardiac biomarker testing system saves time

Scientists at Singapore's Institute of Microelectronics (IME) have developed a rapid and sensitive integrated system to test simultaneously for specific cardiac biomarkers in finger prick amount of blood.

9 Dec 2009

First-quarter fiscal 2010 results announced by Helix BioPharma

Helix BioPharma Corp. today announced financial results for the first quarter ended October 31, 2009.

9 Dec 2009

Mozobil with chemotherapy may have a therapeutic impact on leukemic cells, reveals study

Genzyme Corporation announced today that a Phase 1/2 trial provided early clinical data suggesting that Mozobil (plerixafor injection) in combination with chemotherapy may offer a therapeutic impact on leukemic cells protected in bone marrow.

9 Dec 2009

GSK updates long-term survival data of BEXXAR Therapeutic Regimen for Non-Hodgkin's lymphoma

GlaxoSmithKline announced today updated long-term survival data from two Phase II studies of BEXXAR® (tositumomab and iodine I-131 tositumomab) used in either patients with previously untreated cancer of the immune system (follicular lymphoma) or in patients with cancer of the lymphocytes (non-Hodgkin's lymphoma, NHL) that no longer responded to rituximab.

9 Dec 2009

Micromet presents final data from its blinatumomab Phase 2 study for ALL

Micromet, Inc., a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced data from its completed phase 2 clinical trial with blinatumomab in patients with B-precursor acute lymphoblastic leukemia (ALL).

8 Dec 2009

BARDA cancels PharmAthene's RFP for Recombinant Protective Antigen Anthrax Vaccine

PharmAthene, Inc. a biodefense company specializing in the development and commercialization of medical countermeasures against chemical and biological threats, announced today that the Department of Health and Human Services Biomedical Research and Development Authority (BARDA) has canceled its request for proposal (RFP) for Recombinant Protective Antigen Anthrax Vaccine for the Strategic National Stockpile (RFP BARDA 08-15).

8 Dec 2009

AbSorber receives patent protection for its XM-ONE in the European countries

AbSorber has received patent protection for its transplantation cross match-test XM-ONE® in the European countries. The patent was previously approved in New Zealand which was the first country to approve a patent for AbSorbers product.

8 Dec 2009

EPO grants patent for AbSorber's transplantation cross match-test

LinkMed’s subsidiary AbSorber has received patent protection for its transplantation cross match-test XM-ONE® in the European countries. The patent was previously approved in New Zealand which was the first country to approve a patent for AbSorbers product. The European countries are highly prioritized markets for AbSorber and the patent approval is an important milestone in Absorbers intellectual property strategy.

8 Dec 2009

Phase III CLL8 trial shows Rituxan plus FC chemotherapy improves patients with CLL

Genentech, Inc., a wholly owned member of the Roche Group, and Biogen Idec today announced that three-year follow up of the pivotal Phase III CLL8 trial showed Rituxan plus fludarabine and cyclophosphamide (FC) chemotherapy helped patients in the trial with previously untreated chronic lymphocytic leukemia (CLL) live longer than FC alone.

8 Dec 2009

Neovacs announces initiation of a Phase IIa clinical study of TNFα Kinoid immunotherapy

Neovacs, a biotechnology company developing proprietary immunotherapies for autoimmune and chronic diseases, today announced the initiation of a Phase IIa clinical study of its TNFα Kinoid immunotherapy in rheumatoid arthritis patients who have ceased to respond to an anti-TNFα monoclonal antibody and who test positive for anti-drug antibodies (ADAs).

8 Dec 2009

ImmunoGen's SAR3419 holds hope for B-cell non-Hodgkin’s lymphoma

ImmunoGen, Inc., a biopharmaceutical company that develops targeted anticancer therapeutics, today announced the presentation of encouraging initial clinical findings with SAR3419 at the American Society of Hematology (ASH) 51st Annual Meeting and Exposition. Among the findings reported were responses to SAR3419 – administered as a single agent – among patients with B-cell non-Hodgkin's lymphoma that is refractory to treatment with rituximab (Rituxan®).

8 Dec 2009

Galapagos NV receives milestone payment to initiate Phase I clinical trial of GLPG0555 drug

Galapagos NV (Euronext: GLPG) announced today that it has initiated clinical Phase I development of the first small molecule candidate from its arthritis alliance with GlaxoSmithKline (GSK).

8 Dec 2009

Novo Nordisk in-licenses intellectual property rights to IL-21 antibodies

Novo Nordisk A/S and ZymoGenetics, Inc. today announced an agreement where Novo Nordisk in-licenses a fully-human anti-IL21 monoclonal antibody (IL-21 mAb) developed by ZymoGenetics, as well as broad intellectual property rights covering IL-21 mAb and the development of other IL-21 antibodies.

From Novo Nordisk 8 Dec 2009

Potentially promising data from Phase I/II study of elotuzumab presented at ASH 2009

Facet Biotech Corporation and Bristol-Myers Squibb Company announced that potentially promising data from a Phase I/II study of elotuzumab, an investigational humanized antibody being studied for the treatment of relapsed multiple myeloma (MM), were presented today at the American Society of Hematology (ASH) 2009 Annual Meeting in New Orleans.

8 Dec 2009

CAM314 randomized Phase 3 clinical trial results released

Genzyme Corporation announced data from its CAM314 randomized Phase 3 clinical trial comparing Campath (alemtuzumab) in combination with Fludara (fludarabine phosphate) (FluCAM) to Fludara alone in patients with relapsed and refractory chronic lymphocytic leukemia (CLL) demonstrated that the FluCAM regimen significantly reduced the risk of disease progression or death compared to single-agent Fludara.

8 Dec 2009

Antibody News and Research

Further Reading

BioSystem Development announces the release of AssayMAP MAb Titer Assay

Additional data from ALS patients enrolled in confirmatory Phase III STAR trial announced

Roche to present data on its Herceptin, Avastin and T-DM1 studies at CTRC-AACR Symposium

Alternative, fast and safe process for producing large quantities of effective flu vaccines

Phase 3 clinical trial results of RG1068 to be discussed

New IME-developed cardiac biomarker testing system saves time

First-quarter fiscal 2010 results announced by Helix BioPharma

Mozobil with chemotherapy may have a therapeutic impact on leukemic cells, reveals study

GSK updates long-term survival data of BEXXAR Therapeutic Regimen for Non-Hodgkin's lymphoma

Micromet presents final data from its blinatumomab Phase 2 study for ALL

BARDA cancels PharmAthene's RFP for Recombinant Protective Antigen Anthrax Vaccine

AbSorber receives patent protection for its XM-ONE in the European countries

EPO grants patent for AbSorber's transplantation cross match-test

Phase III CLL8 trial shows Rituxan plus FC chemotherapy improves patients with CLL

Neovacs announces initiation of a Phase IIa clinical study of TNFα Kinoid immunotherapy

ImmunoGen's SAR3419 holds hope for B-cell non-Hodgkin’s lymphoma

Galapagos NV receives milestone payment to initiate Phase I clinical trial of GLPG0555 drug

Novo Nordisk in-licenses intellectual property rights to IL-21 antibodies

Potentially promising data from Phase I/II study of elotuzumab presented at ASH 2009

CAM314 randomized Phase 3 clinical trial results released

Using single B cell screening to boost antibody discovery eBook

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Latest Life Science News